Bone Degeneration Therapeutics Market Overview
The deterioration of articular cartilage covering the joints is a defining feature of bone degeneration. This cartilage plays a crucial role in allowing joints to move freely and without resistance. However, when cartilage deteriorates, joint flexibility is reduced, which can lead to inflammation, compressed nerves, and pain. While aging is a natural contributor to bone degeneration, other factors such as injuries, congenital disorders, diabetes, and obesity can also fuel this process. Some common symptoms of degenerative bone disorders include joint stiffness, pain that radiates from the back and spreads to the limbs, and inflammation of the affected joints.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/94
Fractures may result from osteoporosis, which is defined by the presence of porous bones.
An increased risk of fractures can result from two levels of bone loss: osteoporosis and osteopenia. Osteopenia refers to a decrease in bone material density, indicating a thinning of bones. Osteoporosis, on the other hand, is a condition of bone degeneration that is characterized by the presence of porous bones. As time goes on, bones gradually lose minerals, structure, and density, making them weaker. Eventually, osteoporosis can cause a bent posture, fractured bones, and loss of height.
When bones become excessively degenerated, they become fragile and highly susceptible to fractures. To determine bone density, several tests such as bone densitometers and dual energy x-ray absorptiometry scans are performed. To alleviate the pain associated with degenerative bone disorders, methods such as prolotherapy can be used to stimulate soft tissue and cartilage repair.
Growth in the market for bone degeneration therapies is being driven by rising obesity rates and rising diabetes prevalence.
The bone degeneration therapeutics market is experiencing growth due to several factors, including a rise in physical inactivity, an increase in obesity rates, and a higher incidence of diabetes. The World Health Organization (WHO) reported that in 2014, approximately 422 million people worldwide were affected by diabetes. This increasing number of diabetic patients is contributing to the expansion of the bone degeneration therapeutics market.
There are numerous items in development to support the market growth for bone degeneration treatments.
The bone degeneration therapeutics market can be categorized by treatment and application. In terms of treatment, it can be segmented into device, drug, and surgery. Braces or sleeves can be utilized to alleviate pain caused by bone degeneration and provide pain relief to orthopedic patients. Regarding drugs, the bone degeneration therapeutics market can be divided into cortisone or steroids, hyaluronic acid, and platelet-rich plasma. Platelet-rich plasma has been effective in reducing pain resulting from arthritis of the knee. Some products, such as PREOB and ALLOB from Bone Therapeutics SA, are in the research pipeline. PREOB received orphan drug designation for osteonecrosis from the U.S. FDA in March 2008. With regards to surgery, the bone degeneration therapeutics market is classified as arthroscopy, high tibial osteotomy, and knee replacement.
By application, the bone degeneration therapeutics market can be segmented as osteoporosis, osteopenia, and spinal fusion. Denosumab injection, also known as Prolia, is an example of a drug used to treat osteoporosis in men, post-menopausal women, people at high risk for fractures, and those who are unable to take or do not respond to other osteoporosis medications. It is also utilized to treat bone loss in men with prostate cancer and women with breast cancer.
The market for bone degeneration therapies in North America is expanding as a result of rising sports injuries and an older population.
The bone degeneration market has significant growth potential in North America, attributed to a high incidence of sports-related injuries, advanced technology availability, a large aging population, robust medical infrastructure, and favorable government reimbursement policies. According to 2016 estimates by Osteoporosis Canada, over 80% of all fractures in individuals over 50 years of age are caused by osteoporosis, and at least one in three women and one in five men experience an osteoporotic fracture during their lifetime.
Asia Pacific is projected to be a rapidly growing market for bone degeneration in the near future, driven by increasing consumer health awareness and the development of advanced diagnostic and treatment facilities in the region.
Bone degeneration therapeutics market: Key players
Several companies are actively involved in the development of therapeutic products for bone degeneration, including Amgen, Inc., Fate Therapeutics, Inc., Bone Therapeutics SA, Juventus Therapeutics, Inc., Kaken Pharmaceutical Co., Ltd., Regenexx, and Se-cure Pharmaceuticals, Ltd.
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/94
Regenexx offers advanced regenerative injection treatments such as stem cell and platelet-rich plasma procedures to address knee pain resulting from arthritis, ligament injuries, and other degenerative conditions.
Bone degeneration therapeutics market: Key Developments
Market leaders are concentrating on expanding their product portfolio by performing human surgical procedures with new therapies. For instance, Anika Therapeutics, Inc. completed its first human surgical procedure with an injectable HA-based bone repair therapy in August 2019. The treatment is designed to treat bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration.
Research and development activities related to bone degeneration are being pursued by major institutions. In July 2019, researchers from the University of California reported in the journal Arthritis Care and Research that Vitamin D supplementation may reduce cartilage degeneration and progression of knee osteoarthritis. These studies are expected to promote longitudinal randomized controlled trials of vitamin D supplementation, which may present growth opportunities for market players.
Product approvals are a key focus for market leaders to expand their product portfolio. For example, in August 2019, the U.S. FDA approved the NEXXT MATRIXX Stand Alone Cervical System from Nexxt Spine LLC for commercial sale via the 510(k) process. The system is designed for use in skeletally mature patients as an adjunct to fusion at one or two contiguous levels (C2-T1) for the treatment of degenerative disc disease.
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Bone Degeneration Therapeutics Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Bone Degeneration Therapeutics Industry Impact
Chapter 2 Global Bone Degeneration Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Bone Degeneration Therapeutics (Volume and Value) by Type
2.3 Global Bone Degeneration Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Bone Degeneration Therapeutics Sales, Consumption, Export, Import by Regions (2017-2023)
Chapter 5 North America Bone Degeneration Therapeutics Market Analysis
Chapter 6 East Asia Bone Degeneration Therapeutics Market Analysis
Chapter 7 Europe Bone Degeneration Therapeutics Market Analysis
Chapter 8 South Asia Bone Degeneration Therapeutics Market Analysis
Chapter 9 Southeast Asia Bone Degeneration Therapeutics Market Analysis
Chapter 10 Middle East Bone Degeneration Therapeutics Market Analysis
Chapter 11 Africa Bone Degeneration Therapeutics Market Analysis
Chapter 12 Oceania Bone Degeneration Therapeutics Market Analysis
Chapter 13 South America Bone Degeneration Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Bone Degeneration Therapeutics Business
Chapter 15 Global Bone Degeneration Therapeutics Market Forecast (2023-2030)
Chapter 16 Conclusions
Research Methodology
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/94
Explore More Insights:
About US
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com